The US Food and Drug Administration has announced the recall of a specific batch of Xanax XR, commonly prescribed for treating anxiety disorder, after it failed to meet quality standards.
The recall involves a particular extended-release tablet formulation at a 3 mg dosage. It was initiated voluntarily by Viatris and applies only to bottles containing 60 tablets of the branded medication, excluding generic alprazolam products.
Cause of Recall: Dissolution Issue
Regulators identified a problem related to how the tablets dissolve in the body. This issue may lead to inconsistent release of the active ingredient, potentially reducing effectiveness or altering the timing of the drug’s action.
Such inconsistencies can impact therapeutic outcomes, particularly for patients requiring stable and predictable dosing.
Risk Classification
The recall has been categorized as a Class II recall, indicating that potential health risks are limited and typically temporary or reversible, with a low likelihood of serious adverse effects.
Pharmacies have been instructed on the recall procedures, while patients are not required to take immediate action.
Medical Warnings for Patients
Despite the low risk level, experts strongly advise against abruptly stopping the medication, as it belongs to the benzodiazepine class, which can cause severe withdrawal symptoms if discontinued suddenly.
Patients who suspect they may have affected batches are encouraged to consult their healthcare provider or pharmacist for guidance.
Preventive Measure for Safety
This recall is considered a precautionary step to ensure drug quality and patient safety, rather than an indication of widespread danger. It highlights the importance of continuous pharmaceutical monitoring and strict quality control.
Patients are always advised to seek professional medical advice before making any changes to their treatment regimen.
